



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1234

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/583,107	07/17/2007	514	1654	33510-US-PCT
APPLICANTS Tim H. Bruemmendorf, Hamburg, GERMANY; Stefan Balabanov, Hamburg, GERMANY; Ulrike Hartmann, Tübingen, GERMANY; Winfried Kammer, Rottenburg-Kiebingen, GERMANY; Alfred Nordheim, Dettenhausen, GERMANY;				
** CONTINUING DATA ***** This application is a 371 of PCT/EP2004/014439 12/17/2004 which claims benefit of 60/531,563 12/19/2003				
** FOREIGN APPLICATIONS *****				
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 03/05/2008				
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input type="checkbox"/> No Verified and Acknowledged <u>/MAURY A AUDET/</u> Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials	STATE OR COUNTRY GERMANY	SHEETS DRAWINGS 0	TOTAL CLAIMS 17
INDEPENDENT CLAIMS 3				
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES				
TITLE Combination Of (A) N-{5-[4-(4-Methyl-1-piperazino-Methyl)-Benzoylamido]-2-Methylphenyl}-4-(3-Pyridyl)-2-Pyrimidine-Amine And (B) At Least One Hypusination Inhibitor And The Use Thereof				
FILING FEE RECEIVED 1030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	